Nanoscope Therapeutics Incis A Clinical Stage Biotechnology Company Based In Texasfocused On Developing Gene Agnostic Optogenetic Therapies To Restore Vision In Patients With Retinal Degenerative Diseasesthe Company Targets Conditions Such As Retinitis Pigmentosastargardt Diseaseand Geographic Atrophyaiming To Provide Solutions For Millions Of Patients With Advanced Vision Loss The Company S Proprietary Multi Characteristic Opsinmcoplatform Utilizes Ambient Light Sensitive Molecules For Vision Restoration Without The Need For External Light Stimulation Devicesnanoscope S Lead Productmco 010Is Currently In Phase 2B Clinical Trials For Retinitis Pigmentosa And Stargardt Diseasehaving Received Fda Fast Track Designation And Orphan Drug Statusadditionallymco 020 Is In Preclinical Development For Geographic Atrophyand The Company Collaborates With Institutions Like The Max Planck Institute To Enhance Its Technologynanoscope Therapeutics Is Dedicated To Creating Innovative Therapies That Address Unmet Needs In The Field Of Retinal Diseases
No conferences found for this company.
| Company Name | Nanoscope Therapeutics Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
